Bio-Techne (TECH)
Market Price (12/14/2025): $58.75 | Market Cap: $9.1 BilSector: Health Care | Industry: Life Sciences Tools & Services
Bio-Techne (TECH)
Market Price (12/14/2025): $58.75Market Cap: $9.1 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% | Weak multi-year price returns2Y Excs Rtn is -62%, 3Y Excs Rtn is -100% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -1.0% |
| Low stock price volatilityVol 12M is 43% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.7% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Biopharmaceutical R&D, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Low stock price volatilityVol 12M is 43% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -62%, 3Y Excs Rtn is -100% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -1.0% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.7% |
Valuation, Metrics & Events
TECH Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
1. Strong Analyst Confidence and Increased Price Targets.
In November 2025, multiple analysts maintained "Strong Buy" or "Buy" ratings for Bio-Techne (TECH) and increased their price targets, with an average target forecasting an 18.20% increase in the stock price over the subsequent year. This positive sentiment from financial analysts could have significantly boosted investor confidence and contributed to an upward movement in the stock.
2. Strategic Share Repurchase Program.
Bio-Techne's Board of Directors initiated a substantial share repurchase program on May 7, 2025, authorizing the company to repurchase $500 million in outstanding shares. This move, exceeding the $5 million threshold, demonstrates management's belief that the company's shares may be undervalued and can act as a significant catalyst for stock appreciation by reducing the number of outstanding shares and signaling financial strength.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TECH Return | 45% | 63% | -36% | -6% | -6% | -16% | 13% |
| Peers Return | 47% | 40% | -23% | -11% | -0% | 2% | 42% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 111% |
Monthly Win Rates [3] | |||||||
| TECH Win Rate | 58% | 75% | 42% | 50% | 42% | 50% | |
| Peers Win Rate | 63% | 77% | 42% | 50% | 43% | 50% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| TECH Max Drawdown | -26% | -1% | -45% | -36% | -19% | -35% | |
| Peers Max Drawdown | -23% | -7% | -36% | -30% | -9% | -27% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: TMO, DHR, A, BIO, RVTY. See TECH Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/12/2025 (YTD)
How Low Can It Go
| Event | TECH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -60.8% | -25.4% |
| % Gain to Breakeven | 155.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -27.2% | -33.9% |
| % Gain to Breakeven | 37.4% | 51.3% |
| Time to Breakeven | 45 days | 148 days |
| 2018 Correction | ||
| % Loss | -35.0% | -19.8% |
| % Gain to Breakeven | 53.8% | 24.7% |
| Time to Breakeven | 127 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -44.3% | -56.8% |
| % Gain to Breakeven | 79.4% | 131.3% |
| Time to Breakeven | 841 days | 1480 days |
Compare to TMO, ILMN, BIO, CRL, AVRT
In The Past
Bio-Techne's stock fell -60.8% during the 2022 Inflation Shock from a high on 9/24/2021. A -60.8% loss requires a 155.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
Trade Ideas
Select past ideas related to TECH. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 15.0% | 15.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -5.1% | -5.1% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.0% | 9.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | -5.1% |
| 04302023 | TECH | Bio-Techne | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -25.3% | -18.9% | -33.7% |
| 10312022 | TECH | Bio-Techne | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 7.3% | -25.9% | -25.9% |
| 04302022 | TECH | Bio-Techne | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -22.0% | -15.4% | -25.6% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 15.0% | 15.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -5.1% | -5.1% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.0% | 9.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | -5.1% |
| 04302023 | TECH | Bio-Techne | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -25.3% | -18.9% | -33.7% |
| 10312022 | TECH | Bio-Techne | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 7.3% | -25.9% | -25.9% |
| 04302022 | TECH | Bio-Techne | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -22.0% | -15.4% | -25.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Bio-Techne
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 183.00 |
| Mkt Cap | 25.6 |
| Rev LTM | 4,801 |
| Op Inc LTM | 903 |
| FCF LTM | 793 |
| FCF 3Y Avg | 823 |
| CFO LTM | 1,035 |
| CFO 3Y Avg | 1,044 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.3% |
| Rev Chg 3Y Avg | -1.1% |
| Rev Chg Q | 3.3% |
| QoQ Delta Rev Chg LTM | 0.8% |
| Op Mgn LTM | 18.7% |
| Op Mgn 3Y Avg | 19.3% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.5% |
| CFO/Rev 3Y Avg | 21.1% |
| FCF/Rev LTM | 16.9% |
| FCF/Rev 3Y Avg | 17.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 25.6 |
| P/S | 4.6 |
| P/EBIT | 25.0 |
| P/E | 34.1 |
| P/CFO | 22.4 |
| Total Yield | 2.5% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 3.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.1% |
| 3M Rtn | 16.8% |
| 6M Rtn | 18.0% |
| 12M Rtn | -5.7% |
| 3Y Rtn | -18.1% |
| 1M Excs Rtn | -3.3% |
| 3M Excs Rtn | 13.4% |
| 6M Excs Rtn | 3.7% |
| 12M Excs Rtn | -19.2% |
| 3Y Excs Rtn | -89.0% |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Protein Sciences | 831 | 846 | 832 | 705 | 555 |
| Diagnostics and Spatial Biology | 326 | 293 | 275 | 228 | 185 |
| Intersegment | 4 | -2 | -2 | -1 | -1 |
| Other revenue | -2 | 0 | |||
| Total | 1,159 | 1,137 | 1,106 | 931 | 739 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Protein Sciences | 355 | 374 | 378 | 330 | 235 |
| Diagnostics and Spatial Biology | 25 | 43 | 49 | 38 | 15 |
| Impact of business held-for-sale | 1 | 0 | |||
| Costs recognized on sale of acquired inventory | -1 | -0 | -2 | -2 | |
| Certain Litigation Charges | -4 | 0 | |||
| Acquisition related expenses and other | -7 | 10 | 19 | -7 | -0 |
| Corporate general, selling, and administrative | -9 | -7 | -5 | -5 | -4 |
| Restructuring and restructuring-related costs | -12 | -4 | -2 | -0 | -0 |
| Impairment of assets held-for-sale | -22 | 0 | |||
| Stock based compensation, inclusive of employer taxes | -40 | -41 | -46 | -52 | -34 |
| Amortization of intangibles | -78 | -76 | -73 | -64 | -61 |
| Eminence impairment | 0 | -19 | |||
| Impact of partially-owned consolidated subsidiaries | 1 | -2 | -2 | ||
| Gain on escrow settlement | 7 | ||||
| Total | 207 | 299 | 297 | 237 | 157 |
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2025 | -1.9% | -3.0% | 1.1% |
| 8/6/2025 | -8.7% | -3.3% | -3.0% |
| 5/7/2025 | 2.2% | 8.2% | 1.4% |
| 2/5/2025 | 3.7% | -5.8% | -12.5% |
| 10/30/2024 | 7.5% | 9.7% | 6.7% |
| 8/7/2024 | -9.5% | -6.3% | -7.6% |
| 5/1/2024 | 16.2% | 22.5% | 22.3% |
| 2/1/2024 | -2.5% | -5.6% | 5.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 11 | 14 |
| # Negative | 10 | 13 | 10 |
| Median Positive | 5.5% | 9.6% | 6.5% |
| Median Negative | -2.2% | -4.9% | -7.3% |
| Max Positive | 16.2% | 23.9% | 25.5% |
| Max Negative | -9.5% | -8.3% | -15.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11052025 | 10-Q 9/30/2025 |
| 6302025 | 8222025 | 10-K 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 2062025 | 10-Q 12/31/2024 |
| 9302024 | 11052024 | 10-Q 9/30/2024 |
| 6302024 | 8222024 | 10-K 6/30/2024 |
| 3312024 | 5062024 | 10-Q 3/31/2024 |
| 12312023 | 2072024 | 10-Q 12/31/2023 |
| 9302023 | 11072023 | 10-Q 9/30/2023 |
| 6302023 | 8232023 | 10-K 6/30/2023 |
| 3312023 | 5082023 | 10-Q 3/31/2023 |
| 12312022 | 2072023 | 10-Q 12/31/2022 |
| 9302022 | 11072022 | 10-Q 9/30/2022 |
| 6302022 | 8242022 | 10-K 6/30/2022 |
| 3312022 | 5092022 | 10-Q 3/31/2022 |
| 12312021 | 2072022 | 10-Q 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |